What's new: Creating your blueprint for a wellness-based community.

Scientific research

Back to previous page

New Alzheimer's drug of questionable value

The American Academy of Neurology recently released a position statement on aducanumab (trade name, Aduhelm), which active aging professionals should become familiar with and can use as a resource for discussions with customers and families.

This is a benefit of membership. If you are not an ICAA member you will need to purchase a membership for access. To learn more, please visit http://www.icaa.cc/membership/whyicaa.htm

icaa 100 members